BS_HZRM07TW
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 30.839999999999996
- os_event
- true
- age_years
- 2.827
- sex
- F
- race
- White
- new_clusters
- C4
- umap1_2d
- 3.872997274
- umap2_2d
- 4.686024148
- umap1_3d
- 0.848855652
- umap2_3d
- -0.549589553
- umap3_3d
- -2.688768728
- dataset
- Med-CBTN
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INFLAMMATORY_RESPONSE+0.360
- ALLOGRAFT_REJECTION+0.350
- IL6_JAK_STAT3_SIGNALING+0.310
- COAGULATION+0.290
- TNFA_SIGNALING_VIA_NFKB+0.290
- P53_PATHWAY+0.280
- UV_RESPONSE_UP+0.260
- NOTCH_SIGNALING+0.250
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.230
- WNT_BETA_CATENIN_SIGNALING+0.230
Top 10 suppressed
- MITOTIC_SPINDLE-0.450
- PROTEIN_SECRETION-0.430
- E2F_TARGETS-0.380
- G2M_CHECKPOINT-0.380
- ANDROGEN_RESPONSE-0.290
- MTORC1_SIGNALING-0.270
- MYC_TARGETS_V1-0.260
- BILE_ACID_METABOLISM-0.220
- PEROXISOME-0.140
- HEME_METABOLISM-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | b2b53efa-8a7b-4871-b6bb-6ebfb5cc0cea | — | — | 0.862 |
| 2 | R281 | — | — | 0.861 |
| 3 | SAMN03290885 | — | — | 0.860 |
| 4 | R60 | — | — | 0.859 |
| 5 | SRR3147742 | — | — | 0.859 |
| 6 | BS_T3H5AY8A | low-grade glioma | — | 0.853 |
| 7 | BS_M8M56Z4Y | pilocytic astrocytoma | — | 0.843 |
| 8 | SJEPD001518_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.839 |
| 9 | 9b308588-5e79-46ab-b186-6edd686695c6 | — | — | 0.835 |
| 10 | SAMN03290921 | — | — | 0.834 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INFLAMMATORY_RESPONSE | 0.360 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.350 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.310 | Inavolisib | — uncovered |
| COAGULATION | 0.290 | Binimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.290 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.280 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.260 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.250 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.230 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.230 | Inavolisib | — uncovered |
| COMPLEMENT | 0.210 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.210 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.200 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.200 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |
| MYOGENESIS | 0.180 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.170 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.170 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.160 | Inavolisib | — uncovered |